Ovarian Masses Flashcards
Ovarian cancer is ___ most common cancer in women
6th
Cases of ovarian Ca with genetic predisposition
10-15%
Lifetime risk of ovarian Ca in general population
1 in 50
Risk of ovarian cancer with BRCA 1
1 in 2
Risk of ovarian cancer BRCA2
1 in 5
Risk of ovarian cancer HNPCC
1 in 10
Peak age incidence of ovarian cancer
60s
Ovarian cancer staging
Stage I - confined to ovary
Stage II - involves 1/both ovaries with pelvic extension OR primary peritoneal cancer
Stage III - involves 1/both ovaries with spread to peritoneum outside of pelvic OR metastasis to retroperitoneal lymph nodes
Stage IV - distant metastasis excluding peritoneal metastasis
Ovarian cancer stage 1A
Limited to 1 ovary with intact capsule
No tumour in surface
Negative washings
Ovarian cancer stage 1B
Same as 1A but involves both ovaries
Ovarian cancer stage 1C1
Limited to one or both ovaries but surgical spill
Ovarian cancer stage 1C2
Capsule ruptured before surgery or tumour on ovary surface
Stage 1C3 ovarian cancer
Malignant cells in ascites or peritoneal washings
Lifetime risk of ovarian cancer with affected 1st degree relative
5%
Ca125 positive in ___% ovarian cancers
80
Tumour markers for ovarian cancer
Ca125
HE4
Ca72.4
Ca19-9
CEA
AFP
HCG
Normal CEA levels in smokers
<5
Best combination of tumour markers in ovarian cancer
Ca125 + HE4
Ovarian cancer stage IIA
Extension or implant on uterus OR fallopian tube
Ovarian cancer stage IIB
Extension to other pelvic peritoneal tissues
Ovarian cancer stage IIIA
Positive retroperitoneal lymph nodes or microscopic metastasis beyond pelvis
Ovarian cancer stage IIIA1
Positive retroperitoneal lymph nodes only
Ovarian cancer stage IIIA1i
Mets <10mm
Ovarian cancer stage IIIA1ii
Mets >10mm
Ovarian cancer stage IIIA2
Microscopic extra pelvic peritoneal involvement + positive retroperitoneal lymph nodes
Ovarian ca stage IIIB
Macroscopic, extrapelvic peritoneal mets <2cm and positive retroperitoneal lymph nodes
Ovarian stage IIIC
Macroscopic extrapelvic peritoneal let’s >2cm + positive retroperitoneal lymph nodes
Includes extension to capsule of liver and spleen without parenchymal involvement
Ovarian cancer stage IVA
Pleural effusion with positive cytology
Ovarian cancer stage IVB
Hepatic or splenic parenchymal mets, mets to extra-abdominal organs or lymph nodes outside of abdominal cavity
Proportion of women presenting with late stage ovarian cancer
70-75%
Neoadjuvant chemo is for ___ cycles
3
Ovarian cancer standard chemotherapy
Carboplatin + paclitaxel
6 cycles at 3 week intervals
Targeted ovarian cancer treatments
Anti-VEGF
PARP inhibitors
Adjuvant chemotherapy is not required for ________ ovarian cancer
Well differentiated tumours up to stage 1B
Follow up after primary therapy of ovarian cancer
3-4 months for first 2 years
6 monthly up to 5 years
Ca125 level in recurrence
Twice the upper limit of normal (70)
Treatment of ovarian cancer recurrence
Platinum based agent if >1yr
Liposomal doxxorubicin if <1yr
Surgery for symptoms palliation
Paracentesis
Treatment of poorly differentiated stage 1A/B or stage 1c - stage II ovarian cancer
Primary surgery
Adjuvant chemo 6 cycles
Stage III and stage IV ovarian cancer treatment
Neoadjuvant chemo 3 cycles, interval debulking then 3 cycles chemo
Chemotherapy in optimally reduced stage III/IV ovarian cancer
Intraperitoneal cisplatin/paclitaxel - improves survival but more side effects
IV chemo carboplatin/cisplatin + palclitaxel
Treatment of suboptimally reduced ovarian cancer stage III/IV
Systemic carboplatin + paclitaxel (60% response with no recurrence in 1 year)
OR
Chemo + further surgery + chemo (no survival benefit
Retroperitoneal lymph nodes are positive in ____ of stage 1 ovarian cancer
22%
Optimal staging surgery for ovarian cancer is ___
midline laparotomy, TAH/BSO, washings, infracolic omentectomy
Random biopsies of pelvic and abdominal peritoneum
Retroperitoneal lymph node sampling (not block dissection)
Classification of platinum sensitivity in recurrent ovarian cancer
Refractory - disease progression during chemo
Resistant - <6 months remission
Responsive - remission for >6 months
5yr SR for ovarian cancer
Stage 1 - 94.5%
Stage 2 - 71.6%
Stage 3 - 31.9%
Stage 4 - 16%
Ultrasound score criteria for RMI
Ascites
Bilateral cysts
Multilocular
Solid areas
Metastases
Dysgerminoma proportion malignant vs benign
97% benign
3% malignant
LDH is raised in
Dysgerminomas (94%)
Dysgerminoma accounts for ___ ovarian malignancies and is bilateral in ____
1%
15%
5yr SR for Dysgerminoma
95%
Recurrence rate for Dysgerminoma
20%
Chemotherapy agent for Dysgerminoma
Platinum based
Abortion risk with surgery in 1st trimester of pregnancy
30%
Timing of surgery for ovarian masses in pregnancy
16-18 weeks
When should Surgery for dermoid cysts in pregnancy be done?
Second trimester
When cyst >6cm
If cysts bilateral
Adjuvant chemotherapy for ovarian malignancy in pregnancy
Methotrexate and cisplatin
5-hydroxyindoleactic acid (5-HIAA) is elevated in which ovarian masses?
Ovarian carcinoid tumours
AFP is secreted by
Yolk sac tumours AKA endodermal sinus tumour
Ovarian tumours that cause precocious puberty
Embryonal carcinoma
Polyembryoma
Granulosa cell tumour
Choriocarcinoma of the ovary
Adnexal masses have a non-ovarian origin in ____ cases
10%
Granulosa cell tumours produce
Oestrogen
Granulosa cell tumours are associated with
Endometrial hyperplasia and cancer in 10%
Inhibin B levels are raised in _____ cancers
Granulosa cell tumours
Immature teratomas account for ___ germ cell tumours
20%
Characteristics of immature teratomas
Unilateral
Arise from ectoderm, endoderm and mesoderm
Commonly contain neural tissue
Grade 1-3
No response to radiotherapy
Brenner tumour origin
Wolffian remnants
Transitional epithelium
Clear cell carcinoma origin
Müllerian ducts